MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

Bibliographic Details
Main Authors: Walter, R F H, Mairinger, F D, Ting, S, Vollbrecht, C, Mairinger, T, Theegarten, D, Christoph, D C, Schmid, K W, Wohlschlaeger, J
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453955/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453955/

Similar Items